GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Other Gross PPE

Transgene (XPAR:TNG) Other Gross PPE : €26.55 Mil (As of Jun. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Transgene Other Gross PPE?

Transgene's Other Gross PPE for the quarter that ended in Jun. 2024 was €26.55 Mil.

Transgene's quarterly Other Gross PPE increased from Jun. 2023 (€11.08 Mil) to Dec. 2023 (€26.15 Mil) and increased from Dec. 2023 (€26.15 Mil) to Jun. 2024 (€26.55 Mil).

Transgene's annual Other Gross PPE increased from Dec. 2021 (€12.33 Mil) to Dec. 2022 (€27.47 Mil) but then declined from Dec. 2022 (€27.47 Mil) to Dec. 2023 (€26.15 Mil).


Transgene Other Gross PPE Historical Data

The historical data trend for Transgene's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Other Gross PPE Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.06 12.20 12.33 27.47 26.15

Transgene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.22 27.47 11.08 26.15 26.55

Transgene Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Transgene Business Description

Traded in Other Exchanges
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.

Transgene Headlines

No Headlines